Fig. 4

Differences in therapeutic responses and tumor immunogenicity among inflammatory response subtypes. A-D Comparison of estimated IC50 values of axitinib, pazopanib, sorafenib, and sunitinib among the three inflammatory response subtypes. E-L Differences in tumor immunogenicity factors including TMB, MSI, aneuploidy score, CTA score, homologous recombination defects, intratumor heterogeneity, mRNAsi, and SNV neoantigens among the subtypes. M Landscape of transcriptional levels, methylation, copy-number amplification, and deletion of immunomodulators across the three subtypes. N-P SubMap analysis demonstrates the similarities in expression patterns between inflammatory response subtypes and responses to anti-PD-1 and anti-CTLA4 in TCGA-KIRC, ICGC and E-MATB-1980 datasets